En Es
Categories

Industry News

AI Software Platform Aims to Synthesize Biomedical Knowledge

By HospiMedica International staff writers
12 Jun 2018

Image: The nference AI platform is designed to assist scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner (Photo courtesy of Shutterstock).nference (Cambridge , MA, USA), which focuses on artificial intelligence (AI)-powered life sciences, is developing an AI software platform to synthesize the exponentially growing biomedical knowledge.

The nference team, comprised of successful serial tech entrepreneurs and leading clinical, data and research scientists trained at Massachusetts Institute of Technology (MIT) and Harvard Medical School, works closely with pharmaceutical partners to solve the challenges in drug discovery and clinical research. This includes the identification of emerging targets and signaling pathways for disease processes with unmet need, stratification of patients in clinical trials, and prioritization of life-cycle opportunities for drugs in development. The nference AI platform plays a central role in augmenting the scientists’ abilities to generate holistic data-driven and unbiased hypotheses in a rapid manner.

nference uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the scientific, regulatory and commercial body of literature. The platform enables a diverse set of applications ranging from R&D to commercial strategy and operations in the life sciences ecosystem. nference is making biomedical knowledge computable, and building its AI platform to serve as the connective fabric for various silos of information that exist across health care enterprises.

“Natural language is the connective fabric across all therapeutic areas and support functions of large pharmaceutical companies,” said Venky Soundararajan, Ph.D., Founder and Chief Scientific Officer of nference and Qrativ. “Our AI platform leverages an ensemble of modern neural networks to decode the structure of literature. This kernel helps establish concordance between context-rich unstructured corpora and deep biological insights from structured databases spanning genomics to real world evidence. This presents a paradigm shift toward hypothesis-free scientific research and AI-augmented R&D decision-making.”

“The nference AI technology is enabling an important step forward in digitizing biology. nference’s approach reimagines big pharma R&D by enabling entirely novel hypotheses to emerge from the triangulation of insights across traditionally siloed structured databases and unstructured text documents,” said Diego Miralles, M.D., scientific advisor to nference and former Head of Johnson & Johnson Innovation. “This powerful platform establishes nference as a leader in the ongoing development of AI-powered drug discovery.”

“In addition to empowering drug discovery, the nference AI technology has the potential to transform both early and late-stage clinical development by allowing trialists and pharmaceutical companies to better guide patient selection and sooner anticipate side effects of novel therapies,” said Michael Gibson, M.D, scientific advisor to nference and Chief Executive Officer of the Baim Institute (Formerly Harvard Clinical Research Institute) and PERFUSE Research Institute at Harvard Medical School.

Related Links:
nference



E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

11 Jun 2018
MEDICA 2018 Launches App Competition for Smart Products
The search for the best health app solutions in the world has begun with the launch of the seventh MEDICA App Competition. The competition is meant for applications for smart phones, smart watches, tablets or AR/VR glasses, but excludes fitness or wellness applications. All submitted applications for the MEDICA App Competition 2018 must have a connection with professional medical technology, and applications from start-ups that are still in the early stage are also invited.
Read More
07 Jun 2018
New AI Algorithm Makes Liver Cancer Surgery Safer
Researchers at the Fraunhofer Institute for Medical Image Computing MEVIS have developed algorithms that analyze patients’ imaging data and calculate surgical risks, making liver cancer surgery safer and easier to plan. Researchers at Fraunhofer have been working on image-processing algorithms for use in medicine since 1998. The method is now widely known among physicians as MEVIS analysis and has become established in practice.
Read More
07 Jun 2018
AI-based Interpretation Tool Receives CE Certification
qXR, an AI-based chest X-ray interpretation tool that detects 15 of the most common chest X-ray abnormalities with an accuracy of more than 90%, has received CE certification. Developed by healthcare AI start-up Qure.ai, qXR has been trained on more than one million chest X-rays and uses a heat map or bounding box to point out abnormalities to the clinician, aiding rapid con?rmation in just milliseconds.
Read More
07 Jun 2018
Global Radiation Detection Market to Reach USD 2 Billion by 2022
The global radiation detection, monitoring, and safety market is expected to grow at a CAGR of 5.7% from USD 1.71 billion in 2017 to USD 2.26 billion by 2022. The market is likely to be driven by rising security threats, increasing prevalence of cancer across the world, growing safety awareness among people working in radiation-prone environments, rising safety concerns following the Fukushima disaster, expanding security budgets of global sporting events, increase in the number of PET/CT scans, growing usage of nuclear medicine and radiation therapy for diagnosis and treatment, and use of drones for radiation monitoring. However, nuclear energy alternatives such as renewable energy, nuclear power phase-out, and shortage of nuclear power workforce, are likely to limit the market growth.
Read More
06 Jun 2018
Siemens Healthineers and ScreenPoint Medical to Develop AI-Based Apps
Siemens Healthineers and ScreenPoint Medical have entered into a partnership to develop artificial intelligence (AI)-based applications for breast imaging. As part of the arrangement, Siemens Healthineers will also acquire a strategic minority stake in ScreenPoint Medical.
Read More
06 Jun 2018
Qure.ai Partners with Teleradiology Solutions for Smarter Diagnoses
Healthcare artificial intelligence (AI) provider, Qure.ai has partnered with Teleradiology Solutions and Telerad Tech to enable smarter and faster diagnoses of X-ray and CT scan data, and reduce costs.
Read More
06 Jun 2018
Algorithms to Enhance Approach for Detecting Tumors
Case Western Reserve University has entered into a collaboration with the Quantum team at Microsoft to use the power of quantum computing for improving patient care. CWRU will use Microsoft’s quantum-inspired algorithms to enhance their approach to detecting cancerous tumors.
Read More
31 May 2018
CerTest Biotec Opens New Facility for Diagnostic Products
CerTest Biotec, a biotechnology company focused on the development and manufacturing of IVD diagnostic products, has opened a new facility in Spain for the research, development and manufacture of molecular diagnostics products.
Read More
31 May 2018
Global Molecular Diagnostics Market to Reach USD 11 Billion by 2023
The global molecular diagnostics market is expected to grow at a CAGR of 8.4% from USD 7.71 billion in 2018 to USD 11.54 billion by 2023, driven by the increasing prevalence of infectious diseases and various types of cancers, rising awareness and acceptance of personalized medicine and companion diagnostics, growth of the biomarker identification market, and advancements in molecular techniques.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions